Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
|ClinicalTrials.gov Identifier: NCT03267173|
Recruitment Status : Unknown
Verified August 2017 by First Affiliated Hospital of Harbin Medical University.
Recruitment status was: Recruiting
First Posted : August 30, 2017
Last Update Posted : August 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer CAR||Drug: Chimeric antigen receptor T cell||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.|
|Actual Study Start Date :||June 15, 2017|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2019|
A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
Drug: Chimeric antigen receptor T cell
Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
Other Name: meso-CAR
- Number of patients with tumor response [ Time Frame: 8 weeks ]Tumor response is assessmented with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Number of patients with adverse event [ Time Frame: 8 weeks ]Asverse event is evaluated with CTCAE, version 4.0
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03267173
|Contact: Wei Yunwei, Dctoremail@example.com|
|Contact: Zhao Lei, Dctorfirstname.lastname@example.org|
|Harbin Medical University||Recruiting|
|Harbin, Heilongjiang, China, 150001|
|Contact: Zhao Lei, Doctor 86-13069890888 email@example.com|
|Study Director:||Wei Yunwei, Dctor||First Affiliated Hospital of Harbin Medical University|